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Background: S-nitrosocysteine is a carrier form of nitric oxide that can be delivered
intravenously. S-nitrosocysteine is rapidly metabolized by plasma (half-life = 2-3
seconds), forming nitric oxide and cysteine. With its short half-life and potent
vasodilatory properties, S-nitrosocysteine may be useful as a pulmonary vasodilat-
ing agent in cases of postoperative and chronic pulmonary hypertension.
Objective: Our objective was to determine the hemodynamic properties of S-
nitrosocysteine on the pulmonary and systemic circulations to assess its potential
utility as a pulmonary vasodilatory agent.
Methods: Eleven adult swine were anesthetized. Thermodilution (Swan-Ganz;
Baxter International, Inc, Deerfield, Ill) and arterial catheters were inserted. Flow
probes were placed around the coronary, renal, superior mesenteric, and iliac arter-
ies. Incremental infusion doses of S-nitrosocysteine (5-80 nmol · kg–1 · min–1) were
delivered into the right atrium. Cardiac output, right and left heart pressures, heart
rate, PaO2, and iliac, renal, coronary, and mesenteric blood flow rates were record-
ed at baseline and at each infusion dose of S-nitrosocysteine.
Results: Low-dose S-nitrosocysteine infusion decreased mean pulmonary artery
pressure (15%, P = .013) without a significant reduction in mean systemic artery
pressure. Higher dose infusions produced further dose-dependent declines in pul-
monary vascular resistance and measurable reductions in systemic vascular resis-
tance (P = .01). At an S-nitrosocysteine dosage of 40 nmol · kg–1 · min–1, there was
a significant reduction in renal (P < .001) and mesenteric (P = .003) blood flow but
no change in iliac (P > .2) or coronary (P > .2) blood flow. Cardiac output remained
constant up to infusion rates of 40 nmol · kg–1 · min–1 (P > .2). Doses higher than
5 nmol · kg–1 · min–1 resulted in a substantial dose-dependent reduction in PaO2
(P < .001), suggesting dilation of atelectatic areas of the lung.
Conclusion: S-nitrosocysteine is a potent vasodilatory agent capable of overcoming
the hypoxic vasoconstrictive response of the lung. Our results suggest it may prove
useful as a pulmonary vasodilatory agent at low doses. Higher dose infusions
reduce mean systemic pressure and lead to compensatory reductions in renal and
mesenteric blood flow without a decrease in cardiac output.
Oftentimes in clinical practice, therapeutic measures are needed tolower pulmonary vascular resistance. Unfortunately, many of theagents used to lower pulmonary vascular resistance also exertadditional undesirable effects on the rest of the cardiovascular sys-tem. Recently, inhaled nitric oxide has enjoyed some clinical suc-cess as a selective pulmonary vasodilating agent. The toxic effects
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of inhaled nitric oxide, as well as the expense of its admin-
istration, limit its widespread clinical utility.1
Nitric oxide is a naturally occurring vasoactive molecule
produced from L-arginine by endothelial cells. Nitric oxide
regulates vascular tone; free nitric oxide acts through a cyclic
guanosine monophosphate–dependent pathway to produce
arterial vasodilation. Nitric oxide is a free radical and, as such,
has a short half-life (<1 second) in plasma.2 Interestingly,
nitric oxide also reacts with elements in the blood, forming
more stable complexes that retain vasodilatory properties. One
such class of compounds, S-nitrosothiols, can be formed under
physiologic conditions from nitric oxide and the thiol groups
of proteins and sulfhydryl amino acids. S-nitrosothiols are
nitric oxide donors that have been identified in the human cir-
culation and are believed to be the primary redox form of nitric
oxide.3 The half-life of the various S-nitrosothiols is longer
than that of nitric oxide itself. This potentially permits nitric
oxide formed at one site to have a vasodilatory effect at anoth-
er site in the circulation.
S-nitrosocysteine, the subject of our current study, is a low-
molecular-weight S-nitrosothiol with a short half-life in plas-
ma (estimates range from 2-30 seconds).4,5 S-nitrosocysteine
is a potent vasodilator. In fact, Myers and colleagues6 origi-
nally postulated that S-nitrosocysteine may be an endotheli-
um-derived relaxing factor. Several in vitro studies have
demonstrated the vasodilatory properties of S-nitrosocysteine.
We postulated that the longer half-life of S-nitrosocysteine,
compared with that of nitric oxide, would allow its delivery
into the right atrium, where its vasodilating effects would be
exerted primarily in the pulmonary vasculature. The majority
of the compound would be spontaneously degraded by the
time it reached the left atrium, thereby having a lesser or min-
imal effect on the systemic circulation. In this study we char-
acterize the in vivo cardiovascular effects of S-nitrosocysteine
and assess its potential clinical utility as a selective pulmonary
vasodilator by using a porcine model. Both the D- and L-iso-
mers of S-nitrosocysteine were evaluated because of previous
reports of a possible stereoselective effect.7
Materials and Methods
Chemical Preparation
Base chemicals were purchased from Sigma-Aldrich Co (St Louis,
Mo). S-D-nitrosocysteine and S-L-nitrosocysteine were synthe-
sized by incubating equimolar concentrations of sodium nitrite,
hydrochloric acid, and the corresponding thiol for 30 minutes at
4°C in the dark. The concentration of the stock solutions was con-
firmed spectrophotometrically by the Griess reaction.8 The
nitrosothiol stock solution was serially diluted in normal saline
solution to a final concentration of 3 mmol/L. The final working
solutions were kept on ice in the dark until the time of use.
Animal Preparation and Experimentation
All procedures, protocols, and anesthetics were approved and
supervised by our institutional animal care committee and institu-
tional research review board. Eleven adult swine (55-65 kg) were
held from feed (but not water) for 1 day before experimentation.
Anesthesia was induced with telazole, 10 mg/kg intramuscularly,
followed by inhaled isoflurane and 2.5 mg of intravenous fentanyl.
After endotracheal intubation, anesthesia was sustained with 1.5%
isoflurane and 1 mg/h intravenous fentanyl. Cutaneous oximetry
and end-tidal carbon dioxide levels were monitored continuously,
and the fraction of inspired oxygen (FIO2) was maintained at 100%
by means of mechanical ventilation. A warming blanket main-
tained normothermia.
Pulmonary artery, right atrial, and pulmonary capillary wedge
pressures, as well as cardiac output, were measured by pulmonary
artery catheters placed through the right external jugular vein.
Systemic arterial pressure was measured with a common carotid
artery catheter.
Electromagnetic flow probes (Carolina Medical, King, NC)
were used to measure regional blood flows. After retroperitoneal
exposure, flow probes were placed around the left renal, superior
mesenteric, and left common iliac arteries. The heart was exposed
by a median sternotomy approach. Coronary blood flow was mea-
sured by a flow probe on either the circumflex or left anterior
descending coronary artery. After placement of the flow probes, all
incisions were closed with skin clips.
The electromagnetic flow probe signals were analyzed by
Statham-Gould SP2202 flowmeters (Gould Instrument Systems,
Valley View, Ohio). Pulmonary artery, right atrial, and systemic
arterial pressures were transduced continuously. Pulmonary capil-
lary wedge pressure was measured periodically by the thermodilu-
tion occlusion technique. Hemodynamic data were continuously
recorded with a Gould 2800S 8-channel chart recorder (Gould
Instrument Systems, Valley View, Ohio). Cardiac output measure-
ments using the thermodilution technique9 were obtained with an
Edwards COM-1 cardiac output computer (Baxter Healthcare
Corp, Edwards Division, Irvine, Calif). Arterial blood gas determi-
nations were made with an Instrumentation Laboratory 1610 blood
gas analyzer (Instrumentation Laboratories, Inc, Lexington, Mass)
at each S-nitrosocysteine infusion dose.
After instrumentation, the animals were allowed to stabilize
hemodynamically (approximately 30 minutes). Baseline record-
ings were then obtained. Next, the intravenous infusion of either D-
or L-S-nitrosocysteine was initiated through the right atrial port of
the pulmonary artery catheter. After the animal stabilized to a
steady state (5 minutes) during infusion, recordings of arterial
pressure, Swan-Ganz catheter readings, cardiac output, and local
blood flow were recorded. Measurements were made at infusion
rates of 0, 5, 10, 20, 40, and 80 nmol · kg–1 · min–1 of S-nitroso-
cysteine. The infusion was then terminated, and baseline record-
ings were obtained again. Blood samples were obtained at each
infusion dose for blood gas analysis and serum nitrosothiol assays.
After completion of the experiment, the animals were killed.
Plasma Nitrosothiol Assay
Blood was collected in 4-mL vacuum tubes containing 0.75 mL of
0.1 mol/L KH2PO4 (pH 4.0) and 0.1 mol/L ethylenediamine
tetraacetic acid. Plasma was obtained by means of centrifugation.
Plasma nitrosothiol concentration was determined by high-pres-
sure liquid chromatography (Waters Co, Milford, Mo), as previ-
ously described by our laboratory.10
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Statistical Analysis
Statistical analysis was performed with SPSS software (SPSS,
Inc, Chicago, Ill). Differences between infusion dose groups
were determined by analysis of variance. Values are presented as
means ± SD.
Results
Hemodynamic data recorded at each infusion rate of S-
nitrosocysteine are presented in Table 1. No significant dif-
ferences whatsoever were detected between the D- and L-
isomers of S-nitrosocysteine in all the measurements made
in the study. Therefore, no stereospecific effect of the com-
pound was identified. As a result, the data presented herein
reflect the results obtained from both the D- and L-isomers
of S-nitrosocysteine.
Systemic and Pulmonary Arterial Pressure
Low-dose S-nitrosocysteine (5 nmol · kg–1 · min–1) had no
significant effect on mean systemic arterial pressure
(Figure 1), whereas the mean pulmonary artery pressure
decreased significantly from baseline (23 ± 4 to 19 ± 4
mm Hg; P = .013, Figure 2). At a slightly higher dose (10
nmol · kg–1 · min–1), both systemic and pulmonary arteri-
al pressures decreased. Systemic and pulmonary arterial
pressures continued to decrease in a dose-dependent fash-
ion at infusion rates above 10 nmol · kg–1 · min–1 (Figures
1 and 2).
Cardiac Performance
No significant differences in cardiac output were observed
throughout the dose range of S-nitrosocysteine studied
(Table 1). Although calculated stroke volume decreased 
(P = .007) at the higher infusion doses of S-nitrosocysteine
(40-80 nmol · kg–1 · min–1), cardiac output was maintained
by a significant increase in heart rate (P = .027). There was
no significant change in either pulmonary capillary wedge
pressure or right atrial pressure to account for the changes in
stroke volume.
TABLE 1. Hemodynamic measurements at varying levels of S-nitrosocysteine
RAP PCWP HR CO SV PVR SVR
(mm Hg) (mm Hg) (beats/min) (L/min) (mL/beat) (dynes · s–1 · cm–5) (dynes · s–1 · cm–5)
0 nmol · kg–1 · min–1 8 ± 3.5 11 ± 4 82 ± 20 4.5 ± 1 56 ± 14 221 ± 76 1082 ± 382
5 nmol · kg–1 · min–1 8 ± 3.2 9 ± 3.8 82 ± 20 4 ± 0.6 51 ± 15 204 ± 69 1001 ± 292
10 nmol · kg–1 · min–1 7 ± 3.3 9 ± 3.8 87 ± 21 4.2 ± 1.1 51 ± 17 172 ± 49 807 ± 209
20 nmol · kg–1 · min–1 7 ± 3.9 9 ± 3.4 90 ± 17 4.2 ± 1.2 48 ± 18 160 ± 47 737 ± 222
40 nmol · kg–1 · min–1 7 ± 3 9 ± 3.3 97 ± 15 4 ± 1.1 43 ± 14 172 ± 98 640 ± 128
80 nmol · kg–1 · min–1 7 ± 3 9 ± 3.5 100 ± 23 3.7 ± 1 38 ± 14 147 ± 49 669 ± 186
Values are given as means ± SD. RAP, Right atrial pressure; PCWP, pulmonary artery capillary wedge pressure; HR, heart rate; CO, cardiac output; SV, stroke
volume; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.
Figure 1. Effect of intravenous S-nitrosocysteine infusion on mean
systemic arterial pressure. Values represent mean ± SD. Asterisks
represent a significant change in pressure compared with base-
line values (P < .05).
Figure 2. Effect of intravenous S-nitrosocysteine infusion on mean
pulmonary arterial pressure. Each symbol represents mean ± SD.
Asterisks represent a significant change in pressure compared
with baseline values (P < .05).
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Regional Blood Flow
Renal and superior mesenteric artery blood flows declined
with increasing infusion rates of S-nitrosocysteine, and the
decrease of these blood flows reached statistical signifi-
cance at infusion rates of 20 nmol · kg–1 · min–1 and higher
(Figure 3). Coronary and iliac artery flows were not statisti-
cally different at any infusion rate of S-nitrosocysteine stud-
ied. Superior mesenteric artery blood flow returned to base-
line within 10 minutes of stopping the S-nitrosocysteine
infusion. Although there was some recovery in renal arteri-
al flow after stopping the 80 nmol · kg–1 · min–1 infusion,
renal arterial flow failed to return to preinfusion levels, even
after 30 minutes.
Arterial Blood Gas Analysis
PaO2 decreased as the S-nitrosocysteine infusion dose
increased, despite maintaining FIO2 at 100%. The decrease
in PaO2 was statistically significant at infusion doses of 10
nmol · kg–1 · min–1 and greater (Figure 4) and recovered to
baseline within 5 minutes after discontinuing the S-nitroso-
cysteine infusion. PaCO2 and the pH remained constant at all
doses of S-nitrosocysteine. 
Plasma S-nitrosothiol Concentration
The relationship between infusion rates and measured plas-
ma concentration of S-nitrosocysteine is shown in Figure 5.
Statistically significant elevations in plasma levels were
obtained at doses of 10 nmol · kg–1 · min–1 and higher (P <
.001). The relationship between infusion dose and measured
arterial plasma concentration approximated linearity.
Discussion
S-nitrosocysteine is a potent vasodilator when administered
intravenously. When used at low doses of 5 nmol · kg–1 ·
min–1 and delivered into the right atrium, its short half-life
permits a reduction in mean pulmonary artery pressure
without a significant effect on mean arterial pressure. At
higher doses, however, a decrease in mean pressure in both
the pulmonary and systemic circulation was observed. It is
important to emphasize that these measurable changes in
pulmonary vascular resistance were documented in animals
with normal pulmonary circulation, and the magnitude of
change may be much more dramatic in pathologic states in
which pulmonary resistance is elevated.11
In clinical practice acute control of pulmonary hyperten-
sion may be necessary after heart or lung transplantation, in
certain congenital heart conditions, and after adult valvular
operations. Intravenous agents currently used to control pul-
monary hypertension all have unwanted side effects on the
cardiovascular system, particularly systemic vasodilation.
The other well-established nitric oxide donors, sodium
nitroprusside and nitroglycerin, when administered intra-
venously, are accompanied by significant systemic arterial
and venous dilation. Our study demonstrates that S-nitroso-
cysteine may be useful as a pulmonary vasodilating agent
with few systemic side effects when used in low doses.
Recently, inhaled aerosolized sodium nitroprusside has been
used in the treatment of pulmonary hypertension.12 It was
effective as a selective pulmonary artery dilator at low doses
but had systemic effects at high doses. At present, its role
Cardiopulmonary Support and Physiology Stuesse et al
Figure 3. Effect of intravenous S-nitrosocysteine infusion on
regional blood flows. Values are percentage changes from base-
line for the superior mesenteric (SMA), renal, iliac, and coronary
arteries. Each symbol represents the mean change in flow.
Asterisks represent a significant change in flow compared with
baseline values (P < .05).
Figure 4. Effect of intravenous S-nitrosocysteine infusion on the
systemic PaO2. Each symbol represents mean ± SD. Asterisks rep-
resent a significant change in partial pressure compared with
baseline values (P < .05).
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remains unclear. Newer ultrashort half-life nitric oxide
donors (ie, PROLI/NO) are under evaluation.13
Another important distinction between the nitric oxide
donors and many other vasodilatory agents is their mecha-
nism of action. Nitric oxide donors act through the cyclic
guanosine monophosphate system. This contrasts with other
agents used as pulmonary artery vasodilators (ie, adenosine,
prostaglandins, prostacyclins, dobutamine, amrinone, and
isoproterenol), the actions of which are mediated though a
cyclic adenosine monophosphate mechanism.14 The effects
of low-dose S-nitrosocysteine may be even more valuable as
a selective pulmonary vasodilator if used in conjunction
with low doses of these other cyclic adenosine monophos-
phate–activating agents.
Inhaled nitric oxide gas has been used with some success
to treat the hypoxia and pulmonary hypertension associated
with adult respiratory distress syndrome and congenital heart
disease. Delivered by means of inhalation, nitric oxide selec-
tively vasodilates the ventilated portions of lung. In the setting
of adult respiratory distress syndrome, it corrects ventilation-
perfusion mismatch and thereby improves oxygenation.15
However, inhaled nitric oxide use has many pitfalls, which
include the development of pulmonary edema, rebound pul-
monary hypertension, and vascular tolerance.16-18 Addition-
ally, inhaled nitric oxide is a very reactive molecule capable of
damaging tissues and thereby contributing to airway and
parenchymal lung injury. In the presence of oxygen, nitric
oxide is quickly converted to nitrogen dioxide, a toxic mole-
cule.1 Nitrogen dioxide formation is accelerated at higher oxy-
gen and nitric oxide concentrations. Other toxic effects may be
mediated by peroxynitrite, a cytotoxic molecule formed from
nitric oxide and superoxide. Interestingly, one study of acute
lung injury showed that pretreatment with inhaled nitric oxide
worsened lung injury, whereas pretreatment with intravenous
sodium nitroprusside tended to mitigate the acute lung
injury.19,20 Moreover, the use of inhaled nitric oxide is expen-
sive, and its delivery is complex. An elaborate system for stor-
age, blending, gas analysis, and scavenging is required. Most
of these problems with nitric oxide inhalation therapy may be
avoided by intravenous administration of less reactive and less
toxic species, such as S-nitrosocysteine.18
Intravenously administered nitric oxide donors dilate the
entire pulmonary vascular bed nonselectively.21 The normal
hypoxic vasoconstrictive response in the lung is overcome,
and atelectatic areas are perfused. This was dramatically
demonstrated in this study by a dose-dependent decrease in
PaO2 during S-nitrosocysteine infusion. Intravenous nitric
oxide donors may be most useful in clinical situations when
the major pathologic condition is increased right ventricular
afterload and not hypoxia.
Clearly, S-nitrosocysteine has other effects in addition to
vasodilation. In high doses systemic vasodilatation occurred
simultaneously with splanchnic vasoconstriction. Cardiac
output remained constant at all infusion doses despite a
dose-dependent increase in heart rate, and thus stroke vol-
ume decreased as the S-nitrosocysteine infusion dose
increased. No alterations in preload were observed. There-
fore, at higher S-nitrosocysteine doses, diastolic ventricular
function may decrease (ie, a decrease in lusitropy). With
overlying changes in regional blood flow, it is difficult to
postulate the exact mechanism, be it within the myocardi-
um, systemic circulation, or both. Others have postulated a
negative inotropic effect of nitric oxide and have even pro-
posed that it may be the sought-after myocardial depression
in sepsis.22 At the low doses used to modulate pulmonary
vascular resistance, these myocardial or systemic circulato-
ry effects are predictably minimal.
We compared D- versus L-S-nitrosocysteine because of
previous reports of a possible stereoselective effect. In the
mesenteric bed and hind limbs of rats, L-S-nitrosocysteine
was a more potent vasodilator than D-S-nitrosocysteine, and
the D-isomer was more effective than the L-isomer in
inhibiting baroreceptor reflex-mediated tachycardia.7 A
stereospecific effect would suggest the mechanism of S-
nitrosocysteine action takes place through a receptor-medi-
ated process. Such stereoselective effects of the isomers
were not seen in our in vivo model, and we conclude that the
cardiovascular effects of S-nitrosocysteine are modulated
through their degradation and the subsequent release of
nitric oxide locally. A similar lack of stereospecificity has
been reported in 2 recent studies in rats, in which the authors
speculate that the effects of S-nitrosothiols on vascular
relaxation are most likely caused by nonenzymatic nitric
oxide release.23,24 However, other possible mechanisms for
the vasoactive properties of S-nitrosocysteine do exist,
including possible direct effects of the nitrosothiol, transni-
trosation, or S-thiolation.5,25,26
Figure 5. Relationship between S-nitrosocysteine intravenous
infusion and nitrosothiol concentration in plasma from arterial
blood. Values represent mean ± SD.
376 The Journal of Thoracic and Cardiovascular Surgery • August 2001
ED
ITO
RIA
L
CH
D
G
TS
A
CD
CPS
CSP
TX
Overall, the results presented herein show promise for S-
nitrosocysteine as a selective pulmonary vasodilating agent
when used at low doses of 1 to 10 nmol · kg–1 · min–1.
Certainly, further studies in human subjects and in models
of pulmonary hypertension are needed before the precise
role of this S-nitrosothiol in clinical practice can be deter-
mined.
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Discussion
Dr Edward Verrier (Seattle, Wash). The authors have
described hemodynamic effects of varying doses of S-nitrosocys-
teine in normal adult sheep. Nitrocysteine is an intravenous carrier
form of nitric oxide, and at very low doses of approximately 5
nmol/kg, this compound appears to selectively reduce pulmonary
vascular resistance and pulmonary artery pressures without sys-
temic effects. At very slightly higher doses, however, from 10 nmol
all the way up to 80 nmol, 2 major effects are noted: a reduction in
systemic vascular resistance with subsequent systemic redistribu-
tion of flow with reductions in renal and mesenteric blood flow and
a significant reduction in arterial oxygenation at a constant FIO2 at
all doses above 5 nmol. The presentation has been excellent, the
article is well written, and the science is sound, although it does
not necessarily recreate the usual clinical scenario of pulmonary
hypertension.
I have one major methodologic concern to address to the
authors and then some concluding concerns when comparing the
intravenous form to the inhaled, more commonly used nitric oxide
form. First, the methodologic concern. You note a concern with
nitric oxide–related toxicity. The usual described toxicity of nitric
oxide relates to the binding of nitric oxide to hemoglobin, displac-
ing oxygen and forming methemoglobin. At relatively low doses,
you note a reduction in arterial oxygenation, yet you did not mea-
sure methemoglobin, a relatively simple assay. How do you know
that the reduction in PaO2 was not due to a similar methemoglobin
toxicity and had nothing to do with your proposed mechanism of
“selectively dilating atelectatic areas of lung?”
The corollary question relates to the fact that S-nitrosocysteine is
an intravenous nitric oxide donor compound, which gets to the vas-
cular smooth muscle through the bloodstream, in comparison with
the inhaled form, which theoretically gets to the vascular smooth
muscle before it gets into the bloodstream, therefore making the
intravenous form potentially more toxic. What are your thoughts?
Dr Stuesse. It is true we did not measure the methemoglobin
levels, and it is possible that they could contribute to the decrease
in the PaO2. However, in previous studies of methemoglobinemia
with nitric oxide donors, the level of methemoglobin was not very
high and probably could not contribute to such a dramatic decline.
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Dr Verrier. The reversibility as soon as the drug is discontin-
ued is striking, which to me makes the methemoglobinemia issue
potentially real.
Dr Stuesse. I believe the short half-life of nitrosocysteine also
can explain why when we turn the infusion off the animal would
recover just as quickly. I think the major difference between intra-
venous nitrosocysteine and inhaled nitric oxide is that inhaled
nitric oxide is delivered only to the ventilated portions of the lung.
Therefore, in a situation of adult respiratory distress syndrome and
poor oxygenation, inhaled nitric oxide is really the treatment of
choice because it increases perfusion of ventilated areas of the
lung. However, nitrosocysteine does the opposite. In the clinical
situation of hypoxia, intravenous infusion of nitrosocysteine could
worsen the condition by increasing the shunt fraction in the lung.
Dr Verrier. You note the toxicity and expense of inhaled nitric
oxide; in reality, in the doses up to 40 ppm of inhaled nitric oxide,
there is no parenchymal damage from the formation of nitrogen
dioxide, which you note in your article, and this has not been
reported clinically to my knowledge. The expense issue in the year
2000 is due to the company with exclusive patent rights charging
exorbitant fees and not because the aerosolized form of nitric oxide
is either difficult or expensive to either make or store. In contrast,
your compound does not look simple to make, as you described
eloquently in your “Materials and Methods” section. It has a very
short half-life, cannot be made up in advance, and cannot be
stored; plus it appears that the intravenous form has a very narrow
therapeutic window. At the University of Washington, we have
used inhaled nitric oxide in over 150 patients with pulmonary
hypertension over the past few years and have not found the deliv-
ery system difficult to use or the inhaled compound toxic at all.
Would you please readdress the toxicity and expense issues in your
closing comments?
Dr Stuesse. Actually the nitrosocysteine is quite easy to create.
I would synthesize it the morning before the experiment. It takes
approximately 15 or 20 minutes. At 4°C, it is stable for several
days. The materials used to create nitrosocysteine are quite inex-
pensive. I believe that there are still problems with inhaled nitric
oxide. The availability, scavenging system, and delivery system are
issues. It is complex and more expensive than intravenous nitroso-
cysteine.
In summary, I think nitrosocysteine is very easy to administer,
has a low cost, and may be applicable in situations in which there
is not systemic hypotension or hypoxia.
Dr David Fullerton (Chicago, Ill). For those in the audi-
ence who are unfamiliar with the work that you have done in
the past, this is one of a series of studies that have been ongo-
ing in your laboratory and have advanced things in a very nice
direction.
I was impressed that the data you presented are really quite
similar to what one would expect if one infused other carriers of
nitric oxide, such as nitroglycerin or nitroprusside. Those, of
course, are clinically available and used on a daily basis. Have you
done any comparison studies, and might this offer an advantage
over either of those 2 molecules?
Dr Stuesse. The theoretic advantages of nitrosocysteine
over those readily available molecules are the following. Its
half-life is considerably shorter. The half-life of nitroprusside
in plasma is 2 to 3 minutes, whereas that of nitrosocysteine is 2
to 3 seconds. As such, you are able to deliver more nitric oxide
to the lung and less to the systemic circulation than with
nitrosocysteine. Nitrosocysteine is also approximately 10-fold
more potent than the other carriers. Finally, we did not find any
significant effects on the venous circulation in contrast to other
agents.
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